No Evidence for Genetic Role of the Tumor Necrosis Factor Pathway in Parkinson's Disease
Ghamgosar Shahkhali, M.; Liu, L.; Somerville, E. N.; Noyce, A. J.; Gan-Or, Z.; Senkevich, K.
Show abstract
Tumor necrosis factor (TNF) inhibition is under investigation as a therapeutic strategy for Parkinsons disease (PD) and REM sleep behavior disorder (RBD), yet supporting genetic evidence is limited. We used Summary-data-based Mendelian Randomization (SMR) to test whether expression level of ten TNF-related genes were causally linked to PD risk, PD progression, or RBD risk. We also analyzed associations between common and rare variants in these genes, and performed pathway specific polygenic risk score analysis, with PD. Overall, our findings do not support a genetic link between the TNF signaling and PD or RBD, arguing against this pathway as a genetically validated therapeutic target.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Large-scale genetic characterization of Parkinson’s disease in the African and African admixed populations 97%
- Genetic Analysis and Natural History of Parkinson’s Disease Due to the LRRK2 G2019S Variant 97%
- Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia 97%
Similar papers in this journal
- Genome-wide dysregulation of histone acetylation in the Parkinsons disease brain 96%
- Whole-Genome Sequencing Analysis Reveals New Susceptibility Loci and Structural Variants Associated with Progressive Supranuclear Palsy 95%
- Transcriptome deregulation of peripheral monocytes in GBA -related Parkinson’s disease 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.